Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04932031 · ClinicalTrials.gov registry record
Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy
A clinical trial, sponsored by Sapere Bio.
- Terminated
- Registry status
- 123
- Enrollment target
NCT04932031: Clinical Trial study, sponsored by Sapere Bio.
NCT04932031 is a clinical trial that was terminated before completion, run by Sapere Bio. The registered enrollment target is 123 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04932031 was terminated before completion, sponsored by Sapere Bio.
- TERMINATED
- Registry status
- 123 participants
- Enrollment target
Study Summary
This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and the University of Alabama at Birmingham (UAB) Hospital). The primary purpose of this study to explore patient- and procedure-based variables that identify patients at risk for developing CIPN during chemotherapy.
Primary Outcome
EORTC QLQ CIPN20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2023-11-01 |
Why NCT04932031 stopped before completion
NCT04932031 is an observational study that tracks outcomes without assigning an intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04932031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04932031 about?
NCT04932031 is a clinical study titled "Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy". This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and ...
What is the current status of trial NCT04932031?
This trial is currently terminated. The enrollment target is 123 participants. The study started on 2022-05-25. Estimated completion is 2023-11-01.
Who is sponsoring clinical trial NCT04932031?
This trial is sponsored by Sapere Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI